Skip to content

Regulus Therapeutics Inc.

CIK 0001505512

← back to feed
Revenue (TTM)
$5M
−100.0% YoY Q1 May 2025
Net Income (TTM)
−$43.2M
−54.3% YoY Q1 May 2025
EPS Diluted (TTM)
−$0.82
+48.1% YoY Q1 May 2025
Gross Margin
—
Q1 May 2025
Operating Margin
-936.7%
Q1 May 2025
Net Margin
-864.0%
Q1 May 2025
Free Cash Flow (TTM)
−$34.18M
Q1 May 2025
Cash
$49.46M
Q1 May 2025
Total Debt
$0
Q1 May 2025
Shares Outstanding
69.23M sh
Q1 May 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings